

## URGENT DRUG RECALL SECOND NOTICE

#### Duloxetine DR Capsules USP 20 mg/30 mg/60 mg

#### **April 22, 2025**

Marketing Firm:	Recalling and Manufacturing Firm:
Rising Health, LLC DBA Rising Pharma Holdings, Inc 2 Tower Center Blvd, 1401A	Aurobindo Pharma Limited Unit-III, Sy No. 313&314, Bachupally Medchal-Malkajgiri Dist.
East Brunswick, New Jersey 08816	Telangana, India.

Dear Valued Customer,

This is to inform you of a product recall involving the below batches of Duloxetine DR Capsules, USP 20mg, 30mg and 60mg:

NDC Number	Product Name and Dosage Strength	Package Size	Lot Number	Expiration Date	
			DT2023003A	Jan-25	
57237-017-60	Duloxetine DR Capsules USP 20mg	60's HDPE Bottle	DT2023007A	Jan-25	
			DT2023008A	Jan-25	
57237-018-99	Duloxetine DR Capsules USP 30mg	1000's HDPE Bottle	DT3023025A	Jan-25	
57237-018-30	Duloxetine DR Capsules USP 30mg	30's HDPE Bottle	DT3023051A	Apr-25	
	Duloxetine DR Capsules USP 60mg		DT6023002A	Dec-24	
57237-019-99		1000's LIDDE Dottle	DT6023048A	Jan-25	
3/23/-019-99		1000's HDPE Bottle	DT6023016A	Dec-24	
			DT6023036A	Dec-24	
	Duloxetine DR Capsules USP 60mg 30's HDP		DT6023053A	Jan-25	
			DT6023061A	Jan-25	
			DT6023068A Jan-25		
57237-019-30		30's HDPE Bottle	DT6023074A	Jan-25	
			DT6023078A	Feb-25	
			DT6023076A	Feb-25	
			DTC24043A	Dec-25	
			DTC24044A	Dec-25	



Rising Health LLC has initiated a voluntary drug product recall for the product Duloxetine DR Capsules USP 20 mg/30 mg/60 mg from USA market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit of 5ppm as stipulated by the FDA.

This product was shipped between the dates of 03/16/2023 - 10/29/2024 and our records indicate that you purchased this product during the dates it was marketed.

As per product information leaflet, description of the product is as below, and the product label is also included along with this letter for your ease of identification:

Product Name	Description	Package Size
Duloxetine DR Capsules USP 20 mg	Green Opaque / Green opaque, size '4' hard gelatin capsule filled with white to off white pellets and imprinted with "X" on Green opaque cap and "01" on Green opaque body with black ink	60's HDPE bottle
Duloxetine DR Capsules USP 30 mg	Blue Opaque / White opaque, size '3' hard gelatin capsule filled with white to off white pellets and imprinted with "X" on Blue opaque cap and "02" on White opaque body with black ink	30's, and 1000's HDPE bottle.
Duloxetine DR Capsules USP 60 mg	Blue Opaque / Green opaque, size '1' hard gelatin capsule filled with white to off white pellets and imprinted with "X" on Blue opaque cap and "03" on Green opaque body with black ink	30's and 1000's HDPE bottle.

This recall is being conducted at a retail level with the knowledge of the U.S. Food and Drug Administration.

#### Action to be taken by the Wholesaler/Retailer:

- 1. Immediately examine your inventory, stop distribution and dispensing this lot, quarantine the product.
- 2. Please carryout a physical count and record this data on the enclosed business response form
- 3. Even if you don't have the recalled product, please email the completed response form to Qualanex, Email: recall@qualanex.com or through Fax: 847-737-3719.
- 5. Once the business response form is received by Qualanex, a return goods authorization will be sent to you. Please return your product along with the return authorization using the postage paid shipping label included in your return packet.



If you have further distributed this recalled product to other wholesalers or retailers, please notify the concerned wholesalers or retailers of this recall. If they have any questions regarding the return of this recall product, please have them contact Qualanex, LLC, 1410 Harris Road |Libertyville, IL 60048, Email: recall@qualanex.com or Office (800) 505-9291.

Contact information regarding the recall:

- 1. If you have any medical questions regarding this recall, please contact Rising's drug safety group at 1-844-874-7464 (8:30 am 5:00 pm EST).
- 2. If you have any general questions regarding the return of this product, please contact Qualanex, LLC, 1410 Harris Road |Libertyville, IL 60048, Email: recall@qualanex.com or Office 800-505-9291

We regret any inconvenience and appreciate your immediate cooperation.

Thank you,


Aishwarya Neti Digitally signed by Aishwarya Neti Date: 2025.04.22 11:37:31 -04'00'

Aishwarya Neti Sr. Manager, Quality Assurance Rising Pharma Holdings, Inc 2 Tower Center Blvd, 14 Fl East Brunswick, NJ, 08816

Email: aneti@risingpharma.com, qa@risingpharma.com

The product label is as shown below:

#### Duloxetine DR Capsules USP 20 mg, 60's count







#### Duloxetine DR Capsules USP 30 mg, 30's count

Rising® NOC 57237-018-30	Each delayed-release capsule centains: 33.7 mg of duloxetine hydrochloride USP	Distributed by: Figure Health, LLC	Made in India	Z
Duloxetine Delayed-Release	equivalent to 30 mg duloxetine. Usual Design: See accompanying literature for closege.	Seddle Brook, NJ 07863	Code: TS/DRUGS/19/1903	3572
Capsules USP	Dispense in a tightly closed container, Keep out of the reach of children.	P142	4786	3 7
90 mg PHARMACIST: Dispense the Medication Guide provided separately to each patient.	Store at 20" to 25"C (88" to 77"F); excursions permitted to 15" to 30"C (50" to 86"F) [see USP Controlled Room Temperature].	1		01830
30 Capsules (Ricol)	Do not use if seal over bettle opening is broken or missing.	 		9
				_


#### Duloxetine DR Capsules USP 30 mg, 1000's count



#### Duloxetine DR Capsules USP 60 mg, 30's count



#### Duloxetine DR Capsules USP 60 mg, 1000's count





Rising [ Duloxetine DR Capsules, USP 20mg, 30mg and 60mg ]

[Retail Level Recall]

[Date: April 22, 2025]

[Second Notice # 450]

### **VOLUNTARY RECALL RESPONSE FORM**

Date Form Completed							
Please fill out this form completely, by do notice and have taken the appropriate act means to Qualanex, Attn: Rec	ion. Once	complete pleas	e retu	rn your re	esponse for	m by any one	
This Response Form is for (Check One)		Customer (Pure	chased	d Directly	from MANU	FACTURER)	
Customer/Store Name:	•						
*DEA #:  *DEA # is required in order to process you	ur form	Debit Memo #	(If App	licable)			
Address:	ar ioiiii_	City/State/Zip					
Contact Name (please print):		Email Address					
		Telephone #:					
		Fax #:					
Please mark your answer - I have checked	my stock	and:					
I <u>do</u> have stock of the recalled item(s)	(Complete	Below Table)	OR	□   <u>do r</u>	not have stoc	k of the recal	ed item(s).
Direct Customers							
Does your response include all your	DC location	ns?			☐ YES	□ NO	
Have you notified your customers of	this recall o	lown to the appr	opriate	level?	☐ YES	□NO	
Non-Direct Customers  Name of Wholesaler/Distributor and a in this recall were purchased from (P							



# Rising [ Duloxetine DR Capsules, USP 20mg, 30mg and 60mg ]

[Retail Level Recall]

[Date: April 22, 2025]

[Second Notice # 450]

NDC	Lot#	Exp. Date	Qty. Case to be returned	Qty. Sealed to be returned	Qty. Partia Bottles to b returned
	DT2023003A	Jan-25			
57237-017-60	DT2023007A	Jan-25			
	DT2023008A	Jan-25			
57237-018-99	DT3023025A	Jan-25			
57237-018-30	DT3023051A	Apr-25			
57227 010 00	DT6023002A	Dec-24			
	DT6023048A	Jan-25			
57237-019-99	DT6023016A	Dec-24			
	DT6023036A	Dec-24			
	DT6023053A	Jan-25			
	DT6023061A	Jan-25			
	DT6023068A	Jan-25			
57237-019-30	DT6023074A	Jan-25			
37237-017-30	DT6023078A	Feb-25			
	DT6023076A	Feb-25			
	DTC24043A	Dec-25			
	DTC24044A	Dec-25			